Market Newsdesk

Company pays $24.9 million principal payment in cash

Company expects to be net term debt free at the end of 2020

SACRAMENTO, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) — Pacific Ethanol, Inc. (NASDAQ: PEIX), a leading producer of specialty alcohols and essential ingredients, announced an amendment to the terms of its credit agreements with CoBank, ACB (CoBank).

The Company, with its borrower subsidiaries, Pacific Ethanol Pekin, LLC and Illinois Corn Processing, LLC paid $24.9 million in connection with the amendments, repaying all term debt and reducing the borrowers’ revolving lines of credit to $30 million in total. At the same time, CoBank and the borrowers agreed to reduce certain reporting requirements and eliminate the requirement of the Chief Restructuring Officer position. With the pay down of the CoBank loans, and previous principal payments on the Company’s senior notes, the Company expects to be net term debt free, meaning its consolidated cash exceeds its remaining term debt, at the end of 2020.

Bryon McGregor, Pacific Ethanol’s CFO, said, “We have resolved all outstanding issues with CoBank through these amendments, further strengthening our balance sheet as we enter the new year. In addition, our operating expenses will decrease as professional fees associated with our lenders are eliminated and we expect to be net term debt free by the end of 2020. We are well positioned to continue to capitalize on opportunities in the specialty alcohols and essential ingredients markets.”

Further details on the amendments can be found in the company’s Form 8-K to be filed with the Securities and Exchange Commission by December 24, 2020.

About Pacific Ethanol, Inc.
Pacific Ethanol, Inc. (PEIX) is a leading producer of specialty alcohols and essential ingredients. The company is focused on products for four key markets: Health, Home & Beauty, Food & Beverage, Essential Ingredients and Renewable Fuels. The company’s customers include major food and beverage companies and consumer products companies. Pacific Ethanol’s subsidiary, Kinergy Marketing LLC, markets all specialty alcohol products for Pacific Ethanol’s distilleries as well as fuel grade ethanol for third parties. Pacific Ethanol’s subsidiary, Pacific Ag. Products LLC, markets wet and dry distillers grains. For more information please visit www.pacificethanol.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements and information contained in this communication that refer to or include Pacific Ethanol’s estimated or anticipated future results or other non-historical expressions of fact are forward-looking statements that reflect Pacific Ethanol’s current perspective of existing trends and information as of the date of the communication. Forward looking statements generally will be accompanied by words such as “anticipate,” “believe,” “plan,” “could,” “should,” “estimate,” “expect,” “forecast,” “outlook,” “guidance,” “intend,” “may,” “might,” “will,” “possible,” “potential,” “predict,” “project,” or other similar words, phrases or expressions. Such forward-looking statements include, but are not limited to, statements concerning Pacific Ethanol’s anticipated cash flows and expectations to be net term debt free by the end of 2020; expectations of lower operating expenses; and Pacific Ethanol’s other plans, objectives, expectations and intentions. It is important to note that Pacific Ethanol’s plans, objectives, expectations and intentions are not predictions of actual performance. Actual results may differ materially from Pacific Ethanol’s current expectations depending upon a number of factors affecting Pacific Ethanol’s business. These factors include, among others, adverse economic and market conditions, including for specialty alcohols and essential ingredients; export conditions and international demand for the company’s products; fluctuations in the price of and demand for oil and gasoline; raw material costs, including production input costs, such as corn and natural gas; and the effects – both positive and negative – of the novel coronavirus. These factors also include, among others, the inherent uncertainty associated with financial and other projections; the anticipated size of the markets and continued demand for Pacific Ethanol’s products; the impact of competitive products and pricing; the risks and uncertainties normally incident to the specialty alcohol production and marketing industries; changes in generally accepted accounting principles; successful compliance with governmental regulations applicable to Pacific Ethanol’s distilleries, products and/or businesses; changes in laws, regulations and governmental policies; the loss of key senior management or staff; and other events, factors and risks previously and from time to time disclosed in Pacific Ethanol’s filings with the Securities and Exchange Commission including, specifically, those factors set forth in the “Risk Factors” section contained in Pacific Ethanol’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 16, 2020.

Company IR Contact:	IR Agency Contact:	Media Contact:
Pacific Ethanol, Inc.	Moriah Shilton	Paul Koehler
916-403-2755	LHA	Pacific Ethanol, Inc.
[email protected]	415-433-3777	916-403-2790
		[email protected]

 

HOUSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) — IES Holdings, Inc. (“IES”) (NASDAQ: IESC) announced today that it has acquired an 80% ownership interest in Bayonet Plumbing, Heating and Air-Conditioning, LLC (“Bayonet”), a Hudson, FL-based provider of residential heating, ventilation and air conditioning (HVAC) and plumbing installation and maintenance services. Robert (Robbie) C. Blankenship, Bayonet’s President and CEO, and his father, Robert N. Blankenship, the founder of Bayonet, will together retain 20% of the ownership interests in Bayonet. Bayonet, with trailing 12-month revenue through September 2020 of approximately $86 million, has locations in several Florida markets, including Tampa and Orlando. Bayonet will become part of IES’s Residential segment and continue to operate under the Bayonet name.

Jeffrey Gendell, Chairman and Chief Executive Officer, said, “The acquisition of Bayonet strategically expands our geographic footprint into the attractive Florida market, while adding two new complementary trades in HVAC and plumbing. We believe the residential market is well-positioned for continued expansion, and this acquisition represents an opportunity for our IES Residential segment to further accelerate its growth.”

Dwayne Collier, President of IES Residential, added, “As we seek to expand our capabilities beyond our core electrical offering, we are thrilled to have found in Bayonet a strong partner with an expertise in residential HVAC and plumbing, long-standing customer relationships, a mix of installation and maintenance revenue and a demonstrated track record of growth. We are pleased to welcome Robbie, Robert and Bayonet’s over 500 dedicated team members to IES and to expand our presence into Tampa, Orlando, and beyond.”

Robbie Blankenship said, “After more than 40 years as a family-owned business, we are excited to join the IES family and continue to serve our customers through the Bayonet brand. Our partnership with IES will enable us to continue as owners and managers, while also providing support to Bayonet, both strategically and financially, toward achieving our growth objectives to broaden our geographic reach and offering.”

ABOUT IES HOLDINGS, INC.

IES is a holding company that owns and manages operating subsidiaries that design and install integrated electrical and technology systems and provide infrastructure products and services to a variety of end markets, including data centers, residential housing, and commercial and industrial facilities. Our more than 5,000 employees serve clients in the United States. For more information about IES, please visit www.ies-co.com.

ABOUT IES RESIDENTIAL

IES’s Residential segment provides electrical installation services for single-family housing and multi-family apartment complexes. For more information about IES Residential, please visit www.iesresidential.com.

ABOUT BAYONET PLUMBING, HEATING AND AIR-CONDITIONING, LLC

Bayonet, established in 1977, is a provider of residential HVAC and plumbing installation, maintenance and service, with operations in several markets in Florida. For more information about Bayonet, please visit www.bayonet-inc.com.

Certain statements in this release may be deemed “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, all of which are based upon various estimates and assumptions that the Company believes to be reasonable as of the date hereof. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “seek,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology. These statements involve risks and uncertainties that could cause the Company’s actual future outcomes to differ materially from those set forth in such statements. Such risks and uncertainties include, but are not limited to, the impact of the COVID-19 outbreak or future epidemics on our business, including the potential for job site closures or work stoppages, supply chain disruptions, construction delays, reduced demand for our services, or our ability to collect from our customers; the ability of our controlling shareholder to take action not aligned with other shareholders; the possibility that certain tax benefits of our net operating losses may be restricted or reduced in a change in ownership or a change in the federal tax rate; the potential recognition of valuation allowances or write-downs on deferred tax assets; the inability to carry out plans and strategies as expected, including our inability to identify and complete acquisitions that meet our investment criteria in furtherance of our corporate strategy, or the subsequent underperformance of those acquisitions; competition in the industries in which we operate, both from third parties and former employees, which could result in the loss of one or more customers or lead to lower margins on new projects; fluctuations in operating activity due to downturns in levels of construction or the housing market, seasonality and differing regional economic conditions; and our ability to successfully manage projects, as well as other risk factors discussed in this document, in the Company’s annual report on Form 10-K for the year ended September 30, 2020 and in the Company’s other reports on file with the SEC. You should understand that such risk factors could cause future outcomes to differ materially from those experienced previously or those expressed in such forward-looking statements. The Company undertakes no obligation to publicly update or revise any information, including information concerning its controlling shareholder, net operating losses, borrowing availability, or cash position, or any forward-looking statements to reflect events or circumstances that may arise after the date of this release.

Forward-looking statements are provided in this press release pursuant to the safe harbor established under the Private Securities Litigation Reform Act of 1995 and should be evaluated in the context of the estimates, assumptions, uncertainties, and risks described herein.

General information about IES Holdings, Inc. can be found at http://www.ies-co.com under “Investor Relations.” The Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, as well as any amendments to those reports, are available free of charge through the Company’s website as soon as reasonably practicable after they are filed with, or furnished to, the SEC.

Contact: Jeffrey Gendell, CEO
IES Holdings, Inc.
713-860-1500

SHENZHEN, China, Dec. 21, 2020 (GLOBE NEWSWIRE) — Meten EdtechX Education Group Ltd. (Nasdaq: METX) (“Meten EdtechX” or the “Company”), a leading omnichannel English language training (“ELT”) service provider in China, today reported strong recovery of its junior ELT business. Gross billings and students enrollments of its junior ELT business in October and November 2020 both exceeded the corresponding period in 2019.

The Company’s junior ELT business continued to maintain its strong performance after the COVID-19 pandemic in China. From January to November 2020, the cumulative gross billings of the junior ELT business have recovered to approximately 76% of the same period in 2019. Moreover, the gross billings of junior ELT business in October and November increased by approximately 49% and 17%, respectively, compared to the same period last year, showing a positive step to profitability.

The renewal and referral income from existing students accounted for approximately 60% of the gross billings, demonstrating the value of the junior ELT in terms of teaching quality, brand reputation and relatively low-cost customer acquisition channels. At the same time, the student enrollment has also recovered month by month with the gradual reopening of offline learning centers. The cumulative new student enrollment from January to November 2020 has recovered to approximately 71% of the same period last year, and the student enrollment in October and November 2020 has increased by approximately 46% and 24%, respectively, compared to the same period of last year. The overall expansion of student enrollment is in line with the Company’s expectation.

In addition to the continuous development of its existing business, the Company also plans to expand market coverage of its junior ELT business so as to explore the potentials or opportunities in the field of K-12 education service. Currently, the Company has launched Chinese and mathematics projects for the first time at its independent junior learning centers in Foshan, Guangdong Province, and Nanchang, Jiangxi Province, and these projects are progressing smoothly.

About Meten EdtechX

Meten EdtechX is a leading ELT service provider in China, delivering English language and future skills training for Chinese students and professionals. Through a sophisticated digital platform and nationwide network of learning centers, the Company provides its services under three industry-leading brands: Meten (adult and junior ELT services), ABC (primarily junior ELT services) and Likeshuo (online ELT). It offers superior teaching quality and student satisfaction, which are underpinned by cutting edge technology deployed across its business, including AI-driven centralized teaching and management systems that record and analyze learning processes in real time.

The Company is committed to improving the overall English language competence and competitiveness of the Chinese population to keep abreast of the rapid development of globalization. Its experienced management is focused on further developing its digital platform and expanding its network of learning centers to deliver a continually evolving service offerings to a growing number of students across China.

For more information, please visit: https://investor.metenedu-edtechx.com.

Safe Harbor Statement

This announcement contains forward-looking statements that involve risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the impact of the COVID-19 outbreak, our ability to attract students without a significant decrease in course fees; our ability to continue to hire, train and retain qualified teachers; our ability to maintain and enhance our “Meten” brand; our ability to effectively and efficiently manage the expansion of our school network and successfully execute our growth strategy; the outcome of ongoing, or any future, litigation or arbitration, including those relating to copyright and other intellectual property rights; competition in the English language training sector in China; changes in our revenues and certain cost or expense items as a percentage of our revenues; the expected growth of the Chinese English language training and private education market; Chinese governmental policies relating to private educational services and providers of such services; health epidemics and other outbreaks in China; and general economic conditions in China. Further information regarding these and other risks is included in our annual report on Form 20-F and other documents filed with the Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no duty to update such information, except as required under applicable law.

For investor and media inquiries, please contact:

Meten EdtechX

Wendy Wang
+86 136-5142-6060
[email protected]

Ascent Investor Relations LLC
Tina Xiao
+1 917-609-0333
[email protected]

CALGARY, Alberta, Dec. 21, 2020 (GLOBE NEWSWIRE) — Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) and Husky Energy Inc. (TSX: HSE) are pleased to announce they have obtained all of the key regulatory approvals required in connection with the previously announced combination of Cenovus and Husky pursuant to a plan of arrangement under the Business Corporations Act (Alberta).

Subject to the satisfaction of customary closing conditions, the transaction is anticipated to formally close on January 1, 2021. Upon completion of the transaction, the combined company will continue to operate as Cenovus Energy Inc. and remain headquartered in Calgary, Alberta.

Advisory

This news release contains certain forward-looking statements and forward-looking information (collectively referred to as “forward-looking information”) within the meaning of applicable securities legislation, including the United States Private Securities Litigation Reform Act of 1995, about our current expectations, estimates and projections about the future, based on certain assumptions made by Cenovus and Husky in light of their experience and perception of historical trends. Although Cenovus and Husky believe that the expectations represented by such forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Forward-looking information in this news release is identified by words such as “anticipated”, “will” or similar expressions and includes suggestions of future outcomes, including statements about the anticipated timing of closing of the transaction.

Readers are cautioned not to place undue reliance on forward-looking information as Cenovus’s actual results may differ materially from those expressed or implied. Cenovus and Husky undertake no obligation to update or revise any forward-looking information except as required by law. Developing forward-looking information involves reliance on a number of assumptions and consideration of certain risks and uncertainties, some of which are specific to Cenovus and/or Husky and others that apply to the industry generally. Material factors or assumptions on which the forward-looking information in this news release is based include successful closing of the transaction within expected timelines.

Additional information about assumptions, risk factors and uncertainties on which the forward-looking information is based and that could cause Cenovus’s actual results to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements are described in Cenovus’s 2020 guidance (dated April 1, 2020), Cenovus’s Management’s Discussion and Analysis (MD&A) for the year ended December 31, 2019 and its MD&A for the period ended September 30, 2020 as well as its Annual Information Form (AIF) and Form 40-F for the period ended December 31, 2019 (each available at cenovus.com).

Husky’s Annual Information Form for the year ended December 31, 2019, MD&A for the three and nine months ended September 30, 2020 and other documents filed with securities regulatory authorities (accessible through the SEDAR website at sedar.com and the EDGAR website at sec.gov) describe some of the risks, material assumptions and other factors that could influence actual results in respect of Husky and are incorporated herein by reference.

About Cenovus

Cenovus Energy Inc. is a Canadian integrated oil and natural gas company. It is committed to maximizing value by sustainably developing its assets in a safe, innovative and cost-efficient manner, integrating environmental, social and governance considerations into its business plans. Operations include oil sands projects in northern Alberta, which use specialized methods to drill and pump the oil to the surface using a technique called steam-assisted gravity drainage (SAGD). The company also has conventional crude oil, natural gas and natural gas liquids assets in Alberta and British Columbia as well as 50% ownership in two U.S. refineries. Cenovus shares trade under the symbol CVE and are listed on the Toronto and New York stock exchanges. For more information, visit cenovus.com.

Find Cenovus on Facebook, Twitter, LinkedIn, YouTube and Instagram.

About Husky

Husky Energy Inc. is a Canadian-based integrated energy company. It is headquartered in Calgary, Alberta, and its common shares are publicly traded on the Toronto Stock Exchange under the symbol HSE. The Company operates in Canada, the United States and the Asia Pacific region with two business segments. The Integrated Corridor includes bitumen from thermal projects in the Lloydminster area of Saskatchewan, along with the Tucker Thermal Project and the Sunrise Energy Project in Alberta, with production integrated into Husky’s downstream operations, which includes upgrading, refining and marketing of refined petroleum products. The Offshore business includes crude oil production offshore Newfoundland and Labrador and natural gas and liquids production offshore China and Indonesia. For more information, visit huskyenergy.com.

Find Husky on Facebook, Twitter, LinkedIn and Instagram.

Cenovus Contacts
Investor Relations Sherry Wendt, Director, Investor Relations 403-766-7711	Media Relations Brett Harris, Manager, Communications 403-766-3420
Husky Contacts
Investor Relations Leo Villegas, Director, Investor Relations 403-513-7817	Media Relations Kim Guttormson, Manager, Communication Services 403-298-7088

 

Lina Saheb and Bryant Edwards Appointed to the Board of Directors

NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) — Brooge Energy Ltd. (“Brooge Energy” or the “Company”) (NASDAQ: BROG), a midstream oil storage and service provider strategically located outside the Strait of Hormuz, adjacent to the Port of Fujairah in the United Arab Emirates (“UAE”) through its wholly-owned subsidiaries Brooge Petroleum and Gas Investment Company FZE (“BPGIC”) and Brooge Petroleum and Gas Investment Company Phase III FZE (“BPGIC III”), today issued a letter to shareholders from its CEO, Nicolaas L. Paardenkooper.

Dear Shareholders,

2020 has been the most significant year of our operating history, and a year of many ‘firsts’ for Brooge Energy as we continue to grow our position as a leading oil storage provider in the Port of Fujairah, UAE. 2020 was our first full year as a public company, following our listing on the NASDAQ in December 2019. It was also the first year during which we secured several new contracts in Phase I at a higher rate than previous contracts which will generate higher margins from fixed storage fees. More recently, in the fourth quarter, we successfully raised $200 million in a bond issuance to clean our Phase I loans, establish a broader investors base and fund the build out of our Phase II facility.

It was also the year we achieved significant milestones with our Phase III development plans by finalizing the Front End Engineering Designs and commencing pre-construction work, including the Soil Investigation and Environmental Impact Assessment (“EIA”) report.

While we are pleased to hit these milestones and proud of our progress this year, we have also faced headwinds resulting from the COVID-19 pandemic. When the situation started to unfold earlier in the year, we demonstrated our operational resilience as Phase I continued to operate unimpeded by COVID-19 restrictions. This was largely achieved due to the advanced-technology and automated features that we invested in when building out the terminals, which allowed us to operate at full capacity despite the reduced workforce. We also continued with the build out of our Phase II storage facility, which is being built to the same award-winning specifications as our Phase I facility. The Phase II facility will expand our storage capabilities to include crude oil, as well as adding more capacity for fuel oil and clean products. While for most of the year Phase II’s construction was not significantly impacted by the virus, we received a confirmation that with the second wave of the pandemic our contractors have experienced supply chain disruptions that have delayed the arrival of manufacturing equipment and other parts necessary for the completion of the build out.

We are now working hard to have the construction of the storage facility completed by the end of Q1 2021 and for the facility to operate at, or near, full capacity by the end of Q2 2021. Phase II is fully contracted, and the signed agreements with customers are not impacted by the launch delay. While we are disappointed about the delay of Phase II’s launch, we are confident that our medium-term trajectory will enable us to generate significantly higher revenues as our capacity expands. After completion of Phase II, our storage capacity will be expanded by approximately 600,000 cbm, which equates to 3.8 million barrels. This increases the total capacity of the BPGIC Terminals to approximately one million cubic meters, or the equivalent of 6.3 million barrels. By this point, we will be the second largest non-captive storage operator in Fujairah.

We believe we have made strong progress throughout 2020, despite the numerous challenges. We are now positioned as a key independent storage provider in Fujairah, UAE, one of the largest global oil export hubs, with capacity to store clean petroleum products and fuel oil using some of the latest technology to maximize company performance and efficiency, while reducing operating costs. Through the development of our Phase II and Phase III facilities, we are also building capacity to store crude oil using similar technology.

As we approach 2021, we are excited about what the future has in store for us. There is a global shortage of oil storage space, and our terminals are in high demand by trading companies that require reliable storage facilities. For trading companies, our services are a necessary lynchpin in the oil supply chain that facilitate their ability to trade physical oil. By investing in the most advanced technology to create high speed terminals, we have positioned BPGIC to capture demand from this lucrative market. This strategy is enabling us to drive higher margins as we have novated some of BPGIC’s contracts, with a total geometric storage capacity of 233,074 cbm, to oil trading companies at a premium to previous contracts, as announced in our press releases dated December 7^th and December 16^th.

To support our growth strategy, we are strengthening our Board of Directors and are pleased to announce the appointment of two new Board members: Ms. Lina Saheb and Mr. Bryant Edwards. Ms. Saheb is the Chief Strategy Officer at Brooge and has over 13 years’ experience in business development roles. As the Chief Strategy Officer, she has been instrumental in spearheading the expansion and future growth of Brooge and plays a vital role in guiding our strategy, corporate development, alliances and partnerships. Bryant Edwards joins the Board as an Independent Director. Mr. Edwards is an accomplished professional with a 35 year legal career, including leading the Latham & Watkins’ expansion in Europe from 2000 to 2008, in the Middle East from 2008 to 2012, and in East Asia from 2012 to 2017. I am delighted to strengthen our Board with the appointment of these talented and experienced individuals who will provide invaluable strategic guidance using their unique skills and knowledge.

We are at an exciting stage of our evolution, and we value your confidence and support as we pursue our growth strategy. By following this course, we are confident that we will expand our revenues even further, and generate improved margins as we continue to establish Brooge as one of the region’s most prominent oil storage providers.

Sincerely,

Nicolaas L. Paardenkooper
Chief Executive Officer

About Brooge Energy Limited

Brooge Energy conducts all of its business and operations through its wholly-owned subsidiaries, Brooge Petroleum and Gas Investment Company FZE (“BPGIC”) and Brooge Petroleum and Gas Investment Company Phase III FZE (“BPGIC III”), Fujairah Free Zone Entities. Brooge Energy is a midstream oil storage and service provider strategically located outside the Strait of Hormuz adjacent to the Port of Fujairah in the United Arab Emirates. Its oil storage business differentiates itself from competitors by providing customers with fast order processing times, excellent customer service and high accuracy blending services with low oil losses. For more information please visit at www.broogeenergy.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties concerning BPGIC’s, BPGIC III’s and Brooge Energy’s expected financial performance, as well as their strategic and operational plans. The actual results may differ materially from expectations, estimates and projections due to a number of risks and uncertainties and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “would,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These risks and uncertainties include, but are not limited to: (1) the ultimate geographic spread, duration and severity of the coronavirus outbreak and the effectiveness of actions taken, or actions that may be taken, by governmental authorities to contain the outbreak or ameliorate its effects; (2) Brooge Energy’s and its subsidiaries’ ability to obtain financing for Phase III on commercially reasonable terms; (3) Brooge Energy’s and its subsidiaries’ ability to negotiate and enter into development and offtake agreements on commercially reasonable terms; (4) the results of technical and design feasibility studies, including the Soil Investigation and the Environmental Impact Assessment report for Phase III; (5) the loss of any end-users; (6) changes in customer demand with respect to ancillary services provided by Brooge Energy and its subsidiaries including throughput, blending, heating, and intertank transfers; (7) Brooge Energy’s and its subsidiaries’ ability to effectively manage the risks and expenses associated with the construction of Phase II, Phase III and other growth and expansion projects; and (8) other risks and uncertainties indicated from time to time in filings with or submissions to the SEC by Brooge Energy. Readers are referred to the most recent reports filed with or furnished to the SEC by Brooge Energy. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact

KCSA Strategic Communications
Valter Pinto / Elizabeth Barker
+1 212-896-1254 or +1 212-896-1203
[email protected]

A second XpresCheck testing location has started construction at Logan International with plans to open in early January in JetBlue’s Terminal C

NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) — XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced expanded COVID-19 testing services for JetBlue Airlines passengers in Boston Logan International Airport, one of the airline’s largest focus cities, through a new partnership with XpresCheck. In early January, XpresCheck will open a new “pop-up” testing facility in JetBlue’s Terminal C. The XpresCheck testing center will offer both rapid and PCR tests with advance appointments recommended.

“As Boston’s leading airline, we are committed to the safety of not only our customers and crewmembers, but also the communities we serve.  By partnering with XpresCheck, a leader in in-airport testing, we are providing our customers traveling to and from the Boston area with innovative testing options.  We appreciate our partners, including Massport, for working with us to bring this important service to our customers,” said Joanna Geraghty, president and chief operating officer, JetBlue Airways.

The new COVID-19 testing center, which will be located prior to security screening, will be available to passengers who may want or need to be tested prior to travel, or those returning to the Boston area. Currently, state officials in Massachusetts require all travelers returning to the state to receive a negative PCR test result that has been administered up to 72 hours prior to arrival. Quarantine is not required after a negative result has been received. Travelers arriving in Boston will be able to simply walk off their flight, grab their bags if needed, and obtain a test without another trip to a medical facility.

 “We are pleased to welcome JetBlue to our network of airline partners, beginning in Boston, as we develop future plans nationally. The JetBlue partnership will bring the convenience of on-site COVID-19 testing to passengers whether traveling to a destination that requires a negative COVID-19 test for entry or returning to Massachusetts and seeking to test out of the state mandated quarantine. The availability of trusted, verifiable health status information, including test results, will continue to help get people back to traveling in 2021,” said Doug Satzman, XpresSpa Group’s chief executive officer.

Passengers seeking more information or who want to make an appointment before and/or after travel should visit www.xprescheck.com. Customers should thoroughly research entry requirements for each destination to determine best timing for testing and accepted testing methods. Entry requirements are subject to change, in some cases with little notice.

About JetBlue Airways

JetBlue is New York’s Hometown Airline®, and a leading carrier in Boston, Fort Lauderdale-Hollywood, Los Angeles, Orlando, and San Juan. JetBlue carries customers across the U.S., Caribbean, and Latin America. For more information, visit jetblue.com.

1. JetBlue offers the most legroom in coach based on average fleet-wide seat pitch for U.S. airlines.
2. Fly-Fi and live television are available on all JetBlue-operated flights. On ViaSat-2 equipped aircraft, Fly-Fi will not be available on portions of some routes, and live television will not be available while operating outside of the contiguous U.S., or until the aircraft returns to the coverage area. On all other aircraft, Fly-Fi and live television will not be available while operating outside of the contiguous U.S., or until the aircraft returns to the coverage area.

About XpresSpa Group, Inc.

XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company. XpresSpa Group’s core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products, with 50 locations in 25 airports globally. Through its XpresTest, Inc. subsidiary, the Company also provides COVID-19 screening and testing under its XpresCheck™ brand at JFK International Airport, Newark Liberty International Airport, Logan International Airport, Phoenix Sky Harbor International Airport, and Denver International Airport. To learn more about XpresSpa Group, visit: www.XpresSpaGroup.com. To learn more about XpresSpa, visit www.XpresSpa.com. To learn more about XpresCheck, visit www.XpresCheck.com.

Forward-Looking Statements

This press release may contain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “should,” “seeks,” “future,” “continue,” or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of various COVID-19 vaccinations as they become available, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our ability further expand our initial sites and our overall ability to manage the regulatory challenges associated with this business line.  Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today’s date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.

Media – XpresSpa

Julie Ferguson
[email protected] 
(312) 385-0098

Investor Relations – XpresSpa

ICR
Raphael Gross
(203) 682-8253

HERZLIYA, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) — Safe-T® Group Ltd. (Nasdaq, TASE: SFET), a provider of secure access solutions for on-premise and hybrid cloud environments, today announced that its wholly-owned subsidiary, NetNut Ltd. (“NetNut”), is entering the defense security market with a newly designed solution.

The new solution – Proxy-In-a-Box – allows law enforcement and other entities in the homeland security market to enjoy NetNut’s unique network capability and have a solution that can be installed completely on premise. The solution enables these organizations to have full control over the way their data is being managed and ensures maximum security and transparency while using the network.

Proxy-In-a-Box allows collection of alternative data. This is the undiscovered data which is not within the traditional data sources (such as social media) and is compiled from various sources. When applying specific analytics on this compiled data, it can cater additional data-driven information that was previously unknown and provide valuable insights with respect to predictive capabilities or behaviors. According to recent report, the global alternative data market size was valued at USD 1.06 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 40.1% from 2020 to 2027¹.

_______________

¹https://www.grandviewresearch.com/industry-analysis/alternative-data-market

NetNut has recently recruited two new managers with extensive experience in the industry and has completed the design of a special configuration of its proxy solution for this industry.

“We found that for such organizations, the ability to fully host the entire access network within their premise is highly important, and as a result, we have designed the solution around these needs. NetNut network’s unique characteristics and the fact it is not relying only on third party end users’ devices, which are completely un-controlled for routing our customers’ traffic, allows us to offer this exclusive solution for the customers in this important market,” said Barak Avitbul, NetNut’s CEO.

“The immediate reaction we received for this product is very positive, and we expect the positive feedback to yield in gains to NetNut” added Mr. Avitbul.

About Safe-T® Group Ltd.

Safe-T Group Ltd. (Nasdaq, TASE: SFET) is a provider of Zero Trust Access solutions which mitigate attacks on enterprises’ business-critical services and sensitive data, while ensuring uninterrupted business continuity. Safe-T’s cloud and on-premises solutions ensure that an organization’s access use cases, whether into the organization or from the organization out to the internet, are secured according to the “validate first, access later” philosophy of Zero Trust. This means that no one is trusted by default from inside or outside the network, and verification is required from everyone trying to gain access to resources on the network or in the cloud.

Safe-T’s wide range of access solutions reduce organizations’ attack surface and improve their ability to defend against modern cyberthreats. As an additional layer of security, our integrated business-grade global proxy solution cloud service enables smooth and efficient traffic flow, interruption-free service, unlimited concurrent connections, instant scaling, and simple integration with our services.

With Safe-T’s patented reverse-access technology and proprietary routing technology, organizations of all size and type can secure their data, services, and networks against internal and external threats.

Safe-T’s SDP solution on AWS Marketplace is available here

For more information about Safe-T, visit www.safe-t.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Safe-T is using forward-looking statements in this press release when it discusses the advantages and the potential of NetNut’s  new solution – Proxy-In-a-Box, the size and trends of the Alternative Data market, and the expectation that the new solution will attract positive feedback and yield in gains to NetNut. Because such statements deal with future events and are based on Safe-T’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Safe-T could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Safe-T’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 31, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Safe-T undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Safe-T is not responsible for the contents of third-party websites.

Investor Relations Contacts:

Gary Guyton
MZ Group – MZ North America
469-778-7844
[email protected]
www.mzgroup.us

Michal Efraty
+972-(0)52-3044404
[email protected]

– Early Data from Study of GPS in Combination with Keytruda^® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks 
and 100% Progression Free Survival at 6 Weeks –

– Early Data from Mesothelioma Study of GPS in Combination with Opdivo^® Shows Clinically Intriguing Activity with Median Progression Free Survival of at Least 10 Weeks –

– Updated Data Expected in First Half of 2021 –

NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced initial data from two clinical studies of galinpepimut-S (GPS), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with checkpoint inhibitor therapies in patients with two different types of advanced solid cancers who had exhausted their standard therapy options.

In the first study, a phase 1/2 ‘basket’ trial of GPS in combination with the checkpoint inhibitor pembrolizumab (Keytruda), which is conducted under a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada), the first set of evaluable patients (n = 8) diagnosed with 2^nd or 3^rd line WT1(+) relapsed or refractory metastatic ovarian cancer demonstrated a disease control rate (the sum of overall response rate and rate of stable disease) of 87.5% with a median follow-up of 9.4 weeks. In this difficult to treat patient population, at the first assessment time-point of 6 weeks post-therapy initiation, 100% of the patients were free of disease progression. Using a validated immunohistochemistry (IHC) assay during the screening period, the rate of WT1 positivity in this ovarian cancer patient population was approximately 70%. Six of the eight evaluable patients are continuing to receive GPS plus pembrolizumab. Enrollment is continuing with a target of a total of 20 patients. More mature clinical and immunobiological data are expected to be announced by the end of the second quarter of 2021.

In the second study, a Phase 1 investigator-sponsored clinical trial (IST) of GPS in combination with the checkpoint inhibitor nivolumab (Opdivo) in patients with macroscopic measurable deposits of malignant pleural mesothelioma (MPM) who were either refractory to or relapsed after frontline tri-modality standard therapy, the first set of evaluable patients (n = 3) had a median progression free survival of at least 10 weeks since therapy initiation. In primary refractory MPM patients, any prolongation of progression-free interval greater than 8 weeks would be considered clinically meaningful, considering the current lack of effective therapies. All patients had the epithelioid variant of MPM, a tumor which is universally expressing WT1.   Moreover, in this study, GPS was found to be appropriately immunogenic, leading to the emergence of antigen (WT1)-specific CD4+ T-memory cell responses at 3 months post-therapy initiation. Additional MPM patients are currently being enrolled; completion of study enrollment (target total n = 10) and more mature clinical and immunobiological data are expected by the end of the second quarter of 2021.

In both studies, the safety profile of the combination of GPS with the checkpoint inhibitor was similar to that seen with checkpoint inhibitors alone, with the addition of only low grade, transitory local reactions at the site of injection of GPS, consistent with previously performed clinical studies of GPS.

“These early data confirm the tolerability profile seen in earlier studies of GPS, which is one of the primary endpoints in these solid cancer trials, in a variety of cancer indications, even in the most refractory patients who underwent numerous prior therapies,” commented Jeffrey S. Weber, MD, PhD, Deputy Director of the Perlmutter Cancer Center at New York University (NYU)-Langone Health, co-Director of its Melanoma Research Program Center and Chair of SELLAS’ Scientific Advisory Board. “These safety findings are accompanied by promising early indications of an efficacy signal for patients with advanced metastatic disease, whose management is extremely challenging even with checkpoint inhibitor monotherapy.”

“We are encouraged by the data shown in these two studies of GPS in combination with checkpoint inhibitors and look forward to additional data from these studies,” stated Dragan Cicic, MD, Senior Vice President, Clinical Development of SELLAS. “We now have early evidence that supports further expanding the field of potential GPS indications into solid cancers with high rates of WT1 positivity.   GPS has previously been shown to invoke multi-epitope, broad cross-reactivity along the full-length of the WT1 protein, suggestive of epitope spreading, and immunologically mediated cancer cell destruction, which are hallmarks of an effective cancer vaccine. The scientific rationale in combining GPS with checkpoint inhibitors is the immunbiologic and pharmacodynamic synergy between the two agents, whereby the negative influence of the tumor microenvironment is mitigated by checkpoint inhibitors and thus allowing the patients’ own immune cells specifically sensitized against WT1, by GPS, to invade and destroy cancerous cells.”  

About the Phase 1/2 Basket Study of GPS in Combination with Pembrolizumab (Keytruda^®) in Patients with Selected WT1-Positive Advanced Cancers, Including Ovarian Cancer

This is a Phase 1/2 open-label, multicenter, multi-arm study conducted under a Clinical Trial Collaboration and Supply Agreement (CTSA) with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) to assess the efficacy and safety of the combination of GPS and pembrolizumab (Keytruda^®) (ClinicalTrials.gov identifier: NCT03761914). The primary endpoints of the study include safety and overall response rate, while secondary endpoints include progression-free survival, overall survival and immune response correlates. The study will enroll approximately 90 patients at up to 20 centers in the United States. The trial is currently evaluating patients with ovarian cancer (second or third line).

About the Phase 1 Trial of GPS in Combination with Nivolumab (Opdivo^®) in Patients with Malignant Pleural Mesothelioma (MPM)

This is a Phase 1 open-label clinical study conducted by Memorial Sloan Kettering Cancer Center (MSK) and is enrolling patients with MPM who harbor relapsed or refractory disease after having received frontline, standard-of-care multimodality therapy (target total n = 10; ClinicalTrials.gov identifier: NCT04040231). The principal investigator for the study is Marjorie G. Zauderer, MD, Co-Director, Mesothelioma Program and Associate Attending Physician in the Thoracic Oncology Service, Department of Medicine at MSK. The trial is investigating the potential of GPS in combination with nivolumab (Opdivo^®) to demonstrate anti-tumor immune responses and meaningful clinical activity in the presence of macroscopic advanced disease in MPM patients and gauging the degree of clinical benefit by assessment of the overall response rate with the combination in comparison with that reported with nivolumab alone in historical comparable patient populations.

Keytruda^® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA, and is not a trademark of SELLAS. The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products. Opdivo^® is a registered trademark of Bristol Myers Squibb, and is not a trademark of SELLAS. The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products.

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from MSK and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S, is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the clinical development of GPS for various cancer indications, including ovarian cancer and MPM, and the potential for GPS as a drug development candidate. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company’s clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 13, 2020 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contacts

Adam Holdsworth
PCG Advisory
917-497-9287
[email protected]

Investor Relations

SELLAS Life Sciences Group, Inc.
917-438-4353
[email protected] 

MONTVALE, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) — MICT, Inc. (Nasdaq: MICT) (“MICT” or the “Company”) today announces its wholly-owned subsidiary GFH Intermediate Holdings Ltd. (GFHI) has launched the Company’s proprietary insurance platform that is expected to be actively offering insurance products by week’s end, ahead of the Company’s anticipated timeline for launch. As a result, the Company believes that it will commence revenue generation from some of its insurance contracts during December 2020.

This announcement comes on the heels of the recently announced partnership with one of the country’s largest payment service providers as well as the signing of a number of insurance agency contracts being completed. China’s nascent market for insurance products is estimated to be the second largest in the world and has been forecasted to overtake the U.S. market by the mid-2030s. Online insurance premiums in China are forecasted to grow 41% annually between 2019 and 2024, with an estimated market size to reach $2.36 trillion by 2032.¹

“We have anticipated this launch for some time and believe that we are providing the Chinese market with superior products and services and believe this will be an important part of our revenue stream moving forward,” commented MICT’s CEO Darren Mercer. “By launching the platform at this time, we will be able to commence revenue generation in December 2020. We also look forward to building significant momentum in the new year and will update shareholders on our progress.”

In addition, the Company wishes to clarify the purpose of the resale registration statement filing made on Friday, December 18, 2020. The filing was not for a new issuance of shares but was made to register a portion of the Company’s currently outstanding restricted shares from certain of its holders.

About MICT

MICT, Inc. (NasdaqCM: MICT) operates through its subsidiaries, GFH Intermediate Holdings Ltd. (“GFHI”) and Micronet Ltd. (“Micronet”). GFHI’s versatile proprietary trading technology platform is designed to serve a large number of high growth sectors in the global fintech space. Primary areas of focus include online brokerage for equities trading and wealth management services and sales of insurance products in several high-growth foreign markets, including Asia, where GFHI owns a substantial database of users. Micronet operates in the growing telematics and commercial Mobile Resource Management market, mainly in the United States and Europe. Micronet designs, develops, manufactures, and sells mobile computing solutions that provide fleet operators and field workforces with computing solutions in challenging work environments.

Forward-Looking Statements

Litigation Reform Act of 1995 and other U.S. Federal securities laws. These forward-looking statements include, but are not limited to, statements related to revenue targets, the growth of the Chinese Insurance market and other statements that are not historical facts. Such forward-looking statements and their implications involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. The forward-looking statements contained in this press release are subject to other risks and uncertainties, including those discussed in the “Risk Factors” section and elsewhere in the Company’s annual report on Form 10-K for the year ended December 31, 2019 and in subsequent filings with the Securities and Exchange Commission. Except as otherwise required by law, the Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Contacts:
[email protected]
(201) 225-0190

¹ Swiss Re Institute and Mordor Intelligence

SAN DIEGO, Dec. 21, 2020 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in critical communications systems and solutions, today announced its inclusion in the recently released Gartner Market Guide for Emergency/Mass Notification Services Solutions by analysts Roberta Witty, David Gregory, Brent Predovich and Mike Gotta. 

From the Market Guide, “Organizations are expanding emergency or mass notification service (EMNS) use cases beyond traditional emergencies (e.g., fires, bombs/bomb threats and natural disasters) to include active intruder/shooter, personnel safety, travel risk management, workforce scheduling, pandemic management, critical IT change/outage notification and industrial accidents. These use cases expand the functionality of the offerings, as well as the level of integration with more applications.”*

“During an emergency or critical event, situational awareness, communications and emergency management are essential,” said Richard S. Danforth, Chief Executive Officer, Genasys Inc. “The Genasys Emergency Management (GEM) platform is the world’s first integrated critical communications solution that addresses enterprise security for the Internet of Things (IoT), automatically discovers at-risk recipients, and sends targeted alerts to their locations on multiple channels.” 

“Our National Emergency Warning System (NEWS) is deployed directly on mobile carrier networks across SMS and cell broadcast channels to send emergency alerts and notifications to residents and visitors with no opt-in required,” Mr. Danforth added. “We believe our inclusion as a Representative Vendor in the Gartner Market Guide recognizes Genasys’ position as a critical communications systems and solutions innovator and leader.” 

*Gartner, Market Guide for Emergency/Mass Notification Services Solutions, November 2020

Gartner Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s Research & Advisory organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Genasys Inc.
Genasys^™ is a global provider of critical communications systems and solutions to help keep people safe. Genasys provides a multi-channel approach to deliver geo-targeted alerts, notifications, instructions and information before, during and after public safety threats and critical business events. The Company’s unified critical communications platform includes Genasys Emergency Management (GEM) applications, National Emergency Warning Systems (NEWS), LRAD^® long-range voice broadcast systems and more.

Genasys systems are in service in 72 countries and in more than 450 U.S. cities in a range of diverse applications, including public safety, emergency warning, mass notification, critical event management, defense, law enforcement, homeland security and many more. For more information, visit genasys.com.

Forward-Looking Statements
Except for historical information contained herein, the matters discussed are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on these statements. We base these statements on particular assumptions that we have made in light of our industry experience, the stage of product and market development as well as our perception of historical trends, current market conditions, current economic data, expected future developments and other factors that we believe are appropriate under the circumstances. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, including without limitation the business impact of health crises or outbreaks of disease, such as epidemics or pandemics, and other risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. Risks and uncertainties are identified and discussed in our filings with the Securities and Exchange Commission. These forward-looking statements are based on information and management’s expectations as of the date hereof. Future results may differ materially from our current expectations. For more information regarding other potential risks and uncertainties, see the “Risk Factors” section of the Company’s Form 10-K for the fiscal year ended September 30, 2020. Genasys Inc. disclaims any intent or obligation to update those forward-looking statements, except as otherwise specifically stated.

Investor Relations Contacts
Jim Fanucchi and Satya Chillara
Darrow Associates, Inc.
[email protected]

Media Contact
Phillip Bergman
Viewstream
[email protected]